Abstract
31P-magnetic resonance spectroscopy (31P-MRS) is a non-invasive tool to study high-energy phosphate (HEP) metabolism. We evaluate whether 31P-MRS can detect early changes in kidney HEP metabolism during a 6-month trial with Valsartan. Twenty consecutive stable and normotensive kidney-transplanted patients were enrolled. Nine of them received short-term low-dose Valsartan treatment (80 mg/day) for 6 months, while 11 controls received no medication. Kidney HEP metabolism was evaluated both at baseline and after treatment by 31P-MRS with a 1.5 T system (Gyroscan Intera Master 1.5 MR System; Philips Medical Systems, Best, The Netherlands). Valsartan-treated patients (n = 9) showed a significant increase in β-ATP/Pi ratio, a marker of kidney HEP metabolism (baseline = 1.03 ± 0.08 vs. 6 months = 1.26 ± 0.07, p = 0.03). In contrast, the β-ATP/Pi ratio in the control group (n = 11) did not change (baseline = 0.85 ± 0.10 vs. 6 months = 0.89 ± 0.08, ns). The improvement in the β-ATP/Pi ratio was not associated with a reduction in arterial blood pressure or in urinary albumin excretion. Kidney-localized 31P-MRS can detect early changes in kidney HEP metabolism during a short-term low-dose Valsartan treatment in stable normotensive kidney-transplanted patients.
| Original language | English |
|---|---|
| Journal | Acta Diabetologica |
| Volume | 49 |
| Issue number | 1 SUPPL. |
| DOIs | |
| Publication status | Published - Dec 2012 |
Fingerprint
Keywords
- Angiotensin receptor antagonists
- Kidney spectroscopy
- Kidney transplantation
ASJC Scopus subject areas
- Endocrinology
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
Cite this
31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients. / Fiorina, Paolo; Bassi, Roberto; Gremizzi, Chiara; Vergani, Andrea; Caldara, Rossana; Mello, Alessandra; Del Maschio, Alessandro; De Cobelli, Francesco; Perseghin, Gianluca; Secchi, Antonio.
In: Acta Diabetologica, Vol. 49, No. 1 SUPPL., 12.2012.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - 31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients
AU - Fiorina, Paolo
AU - Bassi, Roberto
AU - Gremizzi, Chiara
AU - Vergani, Andrea
AU - Caldara, Rossana
AU - Mello, Alessandra
AU - Del Maschio, Alessandro
AU - De Cobelli, Francesco
AU - Perseghin, Gianluca
AU - Secchi, Antonio
PY - 2012/12
Y1 - 2012/12
N2 - 31P-magnetic resonance spectroscopy (31P-MRS) is a non-invasive tool to study high-energy phosphate (HEP) metabolism. We evaluate whether 31P-MRS can detect early changes in kidney HEP metabolism during a 6-month trial with Valsartan. Twenty consecutive stable and normotensive kidney-transplanted patients were enrolled. Nine of them received short-term low-dose Valsartan treatment (80 mg/day) for 6 months, while 11 controls received no medication. Kidney HEP metabolism was evaluated both at baseline and after treatment by 31P-MRS with a 1.5 T system (Gyroscan Intera Master 1.5 MR System; Philips Medical Systems, Best, The Netherlands). Valsartan-treated patients (n = 9) showed a significant increase in β-ATP/Pi ratio, a marker of kidney HEP metabolism (baseline = 1.03 ± 0.08 vs. 6 months = 1.26 ± 0.07, p = 0.03). In contrast, the β-ATP/Pi ratio in the control group (n = 11) did not change (baseline = 0.85 ± 0.10 vs. 6 months = 0.89 ± 0.08, ns). The improvement in the β-ATP/Pi ratio was not associated with a reduction in arterial blood pressure or in urinary albumin excretion. Kidney-localized 31P-MRS can detect early changes in kidney HEP metabolism during a short-term low-dose Valsartan treatment in stable normotensive kidney-transplanted patients.
AB - 31P-magnetic resonance spectroscopy (31P-MRS) is a non-invasive tool to study high-energy phosphate (HEP) metabolism. We evaluate whether 31P-MRS can detect early changes in kidney HEP metabolism during a 6-month trial with Valsartan. Twenty consecutive stable and normotensive kidney-transplanted patients were enrolled. Nine of them received short-term low-dose Valsartan treatment (80 mg/day) for 6 months, while 11 controls received no medication. Kidney HEP metabolism was evaluated both at baseline and after treatment by 31P-MRS with a 1.5 T system (Gyroscan Intera Master 1.5 MR System; Philips Medical Systems, Best, The Netherlands). Valsartan-treated patients (n = 9) showed a significant increase in β-ATP/Pi ratio, a marker of kidney HEP metabolism (baseline = 1.03 ± 0.08 vs. 6 months = 1.26 ± 0.07, p = 0.03). In contrast, the β-ATP/Pi ratio in the control group (n = 11) did not change (baseline = 0.85 ± 0.10 vs. 6 months = 0.89 ± 0.08, ns). The improvement in the β-ATP/Pi ratio was not associated with a reduction in arterial blood pressure or in urinary albumin excretion. Kidney-localized 31P-MRS can detect early changes in kidney HEP metabolism during a short-term low-dose Valsartan treatment in stable normotensive kidney-transplanted patients.
KW - Angiotensin receptor antagonists
KW - Kidney spectroscopy
KW - Kidney transplantation
UR - http://www.scopus.com/inward/record.url?scp=84878834465&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878834465&partnerID=8YFLogxK
U2 - 10.1007/s00592-012-0369-2
DO - 10.1007/s00592-012-0369-2
M3 - Article
C2 - 22302190
AN - SCOPUS:84878834465
VL - 49
JO - Acta Diabetologica
JF - Acta Diabetologica
SN - 0940-5429
IS - 1 SUPPL.
ER -